© Translational lung cancer research. The advent of combination antiretroviral treatment (cART) has been followed by a decrease in HIV-associated morbidity and mortality, but also by an apparent increase in the incidence of non-AIDSdefining cancers (NADCs). The risk of lung cancer is substantially higher in HIV-infected patients than in the general population, in part due to aging and tobacco use, and it is the most frequent NADC. The management of lung cancer in HIV-infected patients has some peculiarities that need to be taken into account. This review focuses on the epidemiology, risk factors, and clinical management of lung cancer in HIV-infected patients. In addition, screening tools and future perspectives are also discussed.
|Journal||Translational Lung Cancer Research|
|Publication status||Published - 1 Jan 2015|
- Antiretroviral treatment
- HIV infection
- Lung cancer
- Non-AIDS-defining cancers (NADCs)